Literature DB >> 17469116

Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

Ian R A Mackenzie1, Eileen H Bigio, Paul G Ince, Felix Geser, Manuela Neumann, Nigel J Cairns, Linda K Kwong, Mark S Forman, John Ravits, Heather Stewart, Andrew Eisen, Leo McClusky, Hans A Kretzschmar, Camelia M Monoranu, J Robin Highley, Janine Kirby, Teepu Siddique, Pamela J Shaw, Virginia M-Y Lee, John Q Trojanowski.   

Abstract

OBJECTIVE: Amyotrophic lateral sclerosis (ALS) is a common, fatal motor neuron disorder with no effective treatment. Approximately 10% of cases are familial ALS (FALS), and the most common genetic abnormality is superoxide dismutase-1 (SOD1) mutations. Most ALS research in the past decade has focused on the neurotoxicity of mutant SOD1, and this knowledge has directed therapeutic strategies. We recently identified TDP-43 as the major pathological protein in sporadic ALS. In this study, we investigated TDP-43 in a larger series of ALS cases (n = 111), including familial cases with and without SOD1 mutations.
METHODS: Ubiquitin and TDP-43 immunohistochemistry was performed on postmortem tissue from sporadic ALS (n = 59), ALS with SOD1 mutations (n = 15), SOD-1-negative FALS (n = 11), and ALS with dementia (n = 26). Biochemical analysis was performed on representative cases from each group.
RESULTS: All cases of sporadic ALS, ALS with dementia, and SOD1-negative FALS had neuronal and glial inclusions that were immunoreactive for both ubiquitin and TDP-43. Cases with SOD1 mutations had ubiquitin-positive neuronal inclusions; however, no cases were immunoreactive for TDP-43. Biochemical analysis of postmortem tissue from sporadic ALS and SOD1-negative FALS demonstrated pathological forms of TDP-43 that were absent in cases with SOD1 mutations.
INTERPRETATION: These findings implicate pathological TDP-43 in the pathogenesis of sporadic ALS. In contrast, the absence of pathological TDP-43 in cases with SOD1 mutations implies that motor neuron degeneration in these cases may result from a different mechanism, and that cases with SOD1 mutations may not be the familial counterpart of sporadic ALS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17469116     DOI: 10.1002/ana.21147

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  353 in total

Review 1.  Local RNA translation at the synapse and in disease.

Authors:  Liqun Liu-Yesucevitz; Gary J Bassell; Aaron D Gitler; Anne C Hart; Eric Klann; Joel D Richter; Stephen T Warren; Benjamin Wolozin
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models.

Authors:  Alexander M Herman; Preeti J Khandelwal; G William Rebeck; Charbel E-H Moussa
Journal:  Exp Neurol       Date:  2012-02-28       Impact factor: 5.330

Review 3.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

4.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 5.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

Review 6.  Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.

Authors:  Daisuke Ito; Norihiro Suzuki
Journal:  Neurology       Date:  2011-09-28       Impact factor: 9.910

7.  Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Authors:  Radhia Benmohamed; Anthony C Arvanites; Jinho Kim; Robert J Ferrante; Richard B Silverman; Richard I Morimoto; Donald R Kirsch
Journal:  Amyotroph Lateral Scler       Date:  2010-11-12

8.  A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease.

Authors:  Tennore Ramesh; Alison N Lyon; Ricardo H Pineda; Chunping Wang; Paul M L Janssen; Benjamin D Canan; Arthur H M Burghes; Christine E Beattie
Journal:  Dis Model Mech       Date:  2010-05-26       Impact factor: 5.758

Review 9.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.

Authors:  Shahram Saberi; Jennifer E Stauffer; Derek J Schulte; John Ravits
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 10.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.